echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Bluestar Genomics' early screening test was recognized by the FDA as a breakthrough medical device

    Bluestar Genomics' early screening test was recognized by the FDA as a breakthrough medical device

    • Last Update: 2021-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, Bluestar Genomics announced that the US FDA has granted its breakthrough medical device designation for non-invasive early screening of pancreatic cancer, which is used to screen pancreatic cancer in newly-onset diabetic patients.


    Pancreatic cancer is called the "king of cancer" because it is difficult to treat and is highly lethal.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.